Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...
Varicocele and Sperm DNA Fragmentation: New Evidence with Implications for Clinical Practice - Beyond the Abstract ...
Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...
ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...
Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...
Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Neeraj Agarwal speaks with Martino Pedrani about integrating aggressive variant prostate cancer tumor suppressor gene (TSG) status into clinical decision-making for metastatic hormone-sensitive ...
Chicago, IL (UroToday.com) Arnaud Mejean, MD, Ph.D, provided the awaited update on the CARMENA trial with longer follow-up results. CARMENA was a randomized phase 3 trial (Figure 1), testing the ...
Zachary Klaassen is joined by Neil Mariados, the lead author on both the SpaceOAR™ and Barrigel® trials to discuss rectal spacing, which is used in radiation therapy to reduce rectal toxicity in ...
Karim Fizazi discusses updated overall survival data from the TALAPRO-2 trial. Dr. Fizazi focuses on the HRR mutation cohort comparing talazoparib plus enzalutamide versus enzalutamide alone in ...
Combination Lenvatinib-Tislelizumab for Fumarate Hydratase-Deficient Renal Cell Carcinoma - Wen Kong
Read the Full Video Transcript Pedro Barata: Hello, everyone. I'm Pedro Barata. I'm a GU oncologist at Case Western Reserve University in Cleveland, Ohio. I'm happy to be here today, joined by Dr. Wen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results